uploads/// Forward EV to EBITDA Multiple for Cannabis Companies

How Aurora Cannabis’s Valuations Compare to Its Peers’


Nov. 20 2020, Updated 1:38 p.m. ET


Investors use valuation multiples as a gauge to determine the value of a stock. Investors closely track these multiples to make entry and exit decisions on stocks.

Let’s look at how Aurora Cannabis’s (ACB) valuation compares to its peers’.

Article continues below advertisement

Aurora versus peers

In the chart above, we’ve compared Aurora Cannabis’s EV-to-EBITDA (enterprise value-to-EBITDA) to those of its peers Canopy Growth (WEED), Tilray (TLRY), and Aphria (APHA). Aurora Cannabis’s most recent valuation multiple is trading at a discount to its peers (HMMJ) Canopy Growth and Tilray.

On January 18, Canopy Growth was trading at an EV-to-EBITDA multiple of 110.9x, Aurora Cannabis was trading at a multiple of 34.2x, and Tilray was trading at a multiple of ~700x. On the other hand, Aphria (APHA) was trading at a discount of 12x to the peer median of 17.7x on the day.

The above valuation multiple takes into account a company’s current EV over its forward EBITDA estimate. Increased leverage makes a stock risky, so it demands a higher return, which will eventually lead to a lower valuation multiple, indicating that investors are pricing in the risk of leverage through higher returns.

For more updates, visit Market Realist’s Healthcare page.


More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.